| [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study MS Hofman, J Violet, RJ Hicks, J Ferdinandus, SP Thang, T Akhurst, ... The Lancet Oncology 19 (6), 825-833, 2018 | 349 | 2018 |
| [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study MS Hofman, J Violet, RJ Hicks, J Ferdinandus, SP Thang, T Akhurst, ... The Lancet Oncology 19 (6), 825-833, 2018 | 349 | 2018 |
| Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised … MS Hofman, N Lawrentschuk, RJ Francis, C Tang, I Vela, P Thomas, ... The Lancet 395 (10231), 1208-1216, 2020 | 160 | 2020 |
| Thyroid autoimmunity and recurrent spontaneous abortion in Iran: a case-control study AT Iravani, MM Saeedi, J Pakravesh, S Hamidi, M Abbasi Endocrine Practice 14 (4), 458-464, 2008 | 83 | 2008 |
| Dosimetry of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes J Violet, P Jackson, J Ferdinandus, S Sandhu, T Akhurst, A Iravani, ... Journal of Nuclear Medicine 60 (4), 517-523, 2019 | 77 | 2019 |
| Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer WP Fendler, M Weber, A Iravani, MS Hofman, J Calais, J Czernin, H Ilhan, ... Clinical Cancer Research 25 (24), 7448-7454, 2019 | 56 | 2019 |
| Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of 177Lu-PSMA-617 theranostics in metastatic castration … J Violet, S Sandhu, A Iravani, J Ferdinandus, SP Thang, G Kong, ... Journal of Nuclear Medicine 61 (6), 857-865, 2020 | 45 | 2020 |
| Poor outcomes for patients with metastatic castration-resistant prostate cancer with low prostate-specific membrane antigen (PSMA) expression deemed ineligible for 177Lu … SP Thang, J Violet, S Sandhu, A Iravani, T Akhurst, G Kong, AR Kumar, ... European urology oncology 2 (6), 670-676, 2019 | 44 | 2019 |
| Cold kit for prostate-specific membrane antigen (PSMA) PET imaging: phase 1 study of 68Ga-Tris (Hydroxypyridinone)-PSMA PET/CT in patients with prostate cancer MS Hofman, P Eu, P Jackson, E Hong, D Binns, A Iravani, D Murphy, ... Journal of Nuclear Medicine 59 (4), 625-631, 2018 | 33 | 2018 |
| TheraP: a randomized phase 2 trial of 177Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial … MS Hofman, L Emmett, J Violet, AY Zhang, NJ Lawrence, M Stockler, ... BJU international 124 (S1), 5-13, 2019 | 30 | 2019 |
| TheraP: A randomised phase II trial of 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC … MS Hofman, L Emmett, SK Sandhu, A Iravani, AM Joshua, JC Goh, ... Journal of Clinical Oncology 38 (15_suppl), 5500-5500, 2020 | 29 | 2020 |
| Advances in urologic imaging: prostate-specific membrane antigen ligand PET imaging MS Hofman, A Iravani, T Nzenza, DG Murphy Urologic Clinics 45 (3), 503-524, 2018 | 21 | 2018 |
| Gallium-68 prostate-specific membrane antigen PET imaging MS Hofman, A Iravani PET clinics 12 (2), 219-234, 2017 | 20 | 2017 |
| Prospective validation of gallium-68 prostate specific membrane antigen-positron emission tomography/computerized tomography for primary staging of prostate cancer LWM van Kalmthout, HHE van Melick, J Lavalaye, RP Meijer, A Kooistra, ... The Journal of urology 203 (3), 537-545, 2020 | 18 | 2020 |
| Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617 J Ferdinandus, J Violet, S Sandhu, RJ Hicks, ASR Kumar, A Iravani, ... European journal of nuclear medicine and molecular imaging 47 (10), 2322-2327, 2020 | 16 | 2020 |
| Theranostics for advanced prostate cancer: current indications and future developments A Farolfi, W Fendler, A Iravani, U Haberkorn, R Hicks, K Herrmann, J Walz, ... European urology oncology 2 (2), 152-162, 2019 | 15 | 2019 |
| Detection of synchronous primary malignancies with 68Ga-labeled prostate-specific membrane antigen PET/CT in patients with prostate cancer: frequency in 764 patients MM Osman, A Iravani, RJ Hicks, MS Hofman Journal of Nuclear Medicine 58 (12), 1938-1942, 2017 | 14 | 2017 |
| Cold Kit PSMA PET Imaging: Phase I study of 68Ga-THP-PSMA PET/CT in patients with prostate cancer MS Hofman, P Eu, P Jackson, E Hong, D Binns, A Iravani, D Murphy, ... Journal of Nuclear Medicine, jnumed. 117.199554, 2017 | 14 | 2017 |
| Intra-individual comparison of 68 Ga-PSMA-11 and 18 F-DCFPyL normal-organ biodistribution G Ferreira, A Iravani, MS Hofman, RJ Hicks Cancer Imaging 19 (1), 1-10, 2019 | 13 | 2019 |
| Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies A Iravani, J Violet, A Azad, MS Hofman Prostate cancer and prostatic diseases 23 (1), 38-52, 2020 | 12 | 2020 |
Professor Michael S. HofmanConsultant Physician, Peter MacCallum Cancer Centre & University of MelbourneVerified email at petermac.org
